Introduction
============

Down syndrome, the most frequent genetic cause of mental retardation occurring in newborns, results from the presence of three copies of chromosome 21 (trisomy 21) ([@B01]). This imbalance of 300 genes causes dysfunctions in developmental and physiological processes, leading to a complex phenotype defined by several clinical features, which are variable in their number and intensity ([@B02]). It is typically associated with physical growth delays, a particular set of facial characteristics, and a severe degree of intellectual disability ([@B03]). Children with Down syndrome may have severe mental retardation ([@B04]) and developmental delay, and they are prone to gastrointestinal malformations ([@B05]). At present, there is no effective drug for treatment of the disease, and, because prenatal diagnosis is the most effective way to avoid the birth of children with Down syndrome, it is important to study the pathogenesis of this disease.

A change in gene expression occurs in trisomy 21 ([@B06]). Antonarakis et al. showed that some characteristics of the Down syndrome phenotype can be related to an increase in expression of two *HSA21* genes: *DSCR1-RCAN1* (regulator of calcineurin activity 1) and the protein kinase *DYRK1A* (dual-specificity tyrosine phosphorylation-regulated kinase). In the developing brain, candidate genes would be involved in neurogenesis, neuronal differentiation, myelination, or synaptogenesis ([@B07]). In Down syndrome, aberrant expression of CRLF2 is associated with mutated JAK2, suggesting that blocking the CRLF2/JAK2 pathway may be an effective method for Down syndrome therapy ([@B08]).

Because the abnormal copy number of chromosome 21 is the main genetic characteristic of the disease, we applied a variety of bioinformatics tools to determine biomarkers of Down syndrome and the transcriptional regulatory network. In the process of identifying differentially expressed genes (DEGs), those genes that showed the greatest up-regulation were selected as biomarkers for Down syndrome. GO (gene ontology) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment for DEGs were used to identify the significantly enriched biological terms and pathways. Finally, a hypergeometric distribution test was applied to select the significantly enriched motifs by transcriptional regulatory network construction.

Material and Methods
====================

Data source
-----------

Raw gene expression data of Down syndrome samples and normal samples were downloaded from the Gene Expression Omnibus (GEO) (<http://www.ncbi.nlm.nih.gov/geo/>) of the National Center for Biotechnology Information (NCBI). GSE 1281 ([@B09]) and GSE 1611 ([@B10]) were from the following GLP81 platform: Affymetrix Murine Genome U74A Version 2 Array. GSE 1281 included six Down syndrome samples and six normal samples, which were from newborn rat brain tissue; GSE 1611 contained 12 samples (Ts1Cje and euploid Down syndrome cerebellum) as follows: two Down syndrome samples at postnatal days 15 and 30, respectively, and two normal samples of newborn at postnatal days 15 and 30, respectively. GSE 5390 ([@B11]) was from the following GPL96 platform: \[HG-U133A\] Affymetrix Human Genome U133A Array, including seven Down syndrome samples from adult humans with Down syndrome and eight normal samples.

Data preprocessing
------------------

The robust multiarray analysis (RMA) algorithm ([@B12]) in Affymetrix Power Tools (APT; <http://www.affymetrix.com/>) was applied to perform background correction and standardization for all raw data, aiming to filter false-positive data. The applied criterion was as follows: at least half the samples had PLIER signal intensity values greater than 100 ([@B13],[@B14]).

Screening of DEGs
-----------------

The screening criteria for DEGs were as follows: signal intensity of Down syndrome samples to normal samples was up-regulated or down-regulated 1.2 times (RMA conversion was 0.26; P\<0.05), and there was at least one group in which the PLIER signal intensity value of half the samples was greater than 100. In order to obtain more DEGs, data in GSE 1281 and GSE 1611 were integrated and normalization performed, while differential analysis of data in different tissue and development stages of Down syndrome samples compared with normal samples were performed separately, and then differential results were combined. We screened up- and down-regulated genes according to the sequence conservation ([@B15]) in human and rat brains. Finally, the genes showing the greatest degree of up-regulation (such as the genes whose signal intensity increased or decreased 1.5 times and with RMA conversion values greater than 0.58) were selected for study.

Gene function annotation
------------------------

The database for annotation, visualization, and integrated discovery (DAVID) ([@B16]) was applied to perform GO function enrichment for DEGs with signal intensity increased or decreased 1.2 times and with RMA where the conversion value was greater than 0.26, and then the significantly enriched GO terms \[P≤0.05, false discovery rate (FDR)≤10\] and KEGG pathways (P≤0.05) were identified.

Construction of the transcriptional regulatory network
------------------------------------------------------

To construct the transcriptional regulatory network, the sequence from 1 kb upstream to 200 bp downstream at the 5′UTR transcription start site of DEGs was extracted, and the JASPAR database ([@B17]) was used to search for transcription factor binding sites (score threshold: 0.95). In addition, because the JASPAR database is limited, the transcriptional regulatory network was constructed combined with transcription factor binding sites in the University of California Santa Cruz (USA) genome browser database ([@B18]). Finally, a hypergeometric distribution test ([@B19]) was applied to select the significantly enriched motifs (P≤0.01).

Results
=======

Identification of DEGs and biomarkers
-------------------------------------

A total of 581 DEGs were identified, in which 227 DEGs were up-regulated and 354 DEGs were down-regulated ([Figure 1A](#f01){ref-type="fig"}). The distribution of DEGs in different development stages of Down syndrome is shown in [Figure 1A](#f01){ref-type="fig"}. A total of 2180 DEGs were identified, in which 2010 were up-regulated and 800 were down-regulated ([Figure 1A](#f01){ref-type="fig"}).

![*A*, Differentially expressed genes (DEGs) in Down syndrome samples compared with normal samples. *B*, Venn diagram of DEGs in human and mouse.](1414-431X-bjmbr-47-10-00834-gf001){#f01}

Generally speaking, the relationship between the transcription factors and their regulatory target genes in human and mouse were conserved. A total of 50 up-regulated and 23 down-regulated DEGs were identified according to orthologous relationships of human *vs* mouse. Nine up-regulated genes *CDKN1C* (cyclin-dependent kinase inhibitor 1C), *DCN* (decorin), *HMGN1* (non-histone chromosomal protein HMG-14), *HSD17B11* (estradiol 17-beta-dehydrogenase 11), *LGALS3BP* (galectin-3-binding protein), *MT2* (metallothionein-2*R*), *RCAN1*, *SON* \[a large Ser/Arg (SR)-related protein\], and *XIST* (X-inactive specific transcript) were up-regulated at least 1.5 times, and the RMA conversion value was greater than 0.58.

Distribution of DEGs in chromosomes
-----------------------------------

[Figure 2A](#f02){ref-type="fig"} demonstrates the distribution of 50 up-regulated genes and 23 down-regulated genes in both human and mouse in the human chromosome. Eight genes of 50 up-regulated DEGs were distributed in human chromosome 21 (mouse chromosome 16), while no down-regulated DEGs were distributed in human chromosome 21 ([Table 1](#t01){ref-type="table"}). Molecular interactions of the following eight genes are shown in [Figure 2B:](#f02){ref-type="fig"} *CBR1* (carbonyl reductase 1), *DYRK1A*, *HMGN1*, *ITSN1* \[intersectin 1 (SH3 domain protein)\], *RCAN1*, *SON*, *TMEM50B* (transmembrane protein 50B), and *TTC3* (tetratricopeptide repeat protein 3). Information on interactions was selected from the BIOGRID database ([@B20]), but *TMEM50B* had no interaction information.

![*A*, Distribution of homologous gene transcripts in both human and mouse in the human chromosome. *B*, Interaction networks of eight genes in chromosome 21. Red nodes represent differentially expressed genes (DEGs), and green nodes represent non-DEGs.](1414-431X-bjmbr-47-10-00834-gf002){#f02}

Gene function and KEGG pathway annotation
-----------------------------------------

The DAVID functional annotation of 73 DEGs is shown in [Figure 3](#f03){ref-type="fig"} (P≤0.05 and FDR≤10). The most significantly enriched biological processes were macromolecular complex subunit organization, cellular ion homeostasis, and synaptic vesicle endocytosis ([Table 2](#t02){ref-type="table"}). A total of 73 KEGG pathways of DEGs is shown in [Table 3](#t03){ref-type="table"} (P≤0.05). The most significantly enriched KEGG pathways were focal adhesion, natural killer cell mediated cytotoxicity, and Alzheimer\'s disease.

![GO (gene ontology) enrichment analysis of 73 differentially expressed genes.](1414-431X-bjmbr-47-10-00834-gf003){#f03}

Transcriptional regulatory network
----------------------------------

The transcriptional regulatory network was constructed according to ortholog genes in human and mouse. The significantly enriched transcription factors in the transcriptional regulatory network are shown in [Figure 4A](#f04){ref-type="fig"}. Eleven significantly (P≤0.01) enriched transcription factor motifs \[*PAX5* (paired box protein Pax-5), *EGR1* (early growth response protein 1), *XBP* (X-box binding protein 1), *SREBP1* (sterol regulatory element-binding transcription factor 1), *OLF1* (human olfactory receptor), *MZF1* (myeloid zinc finger 1), *NFY*, *NFKAPPAB* (nuclear factor kappa B), *MYCMAX*, *NFE2* (transcription factor NF-E2 45 kDa subunit), and *RP58*\] in the transcriptional regulatory network and three motifs in the JASPAR database ([@B17]) are shown in [Figure 4B](#f04){ref-type="fig"}.

![*A*, Transcriptional regulatory network of up-regulated or down-regulated genes. Red triangles denote transcription factors; green circles denote up-regulated genes; pink circles denote down-regulated genes. *B*, Significantly enriched transcription factor motifs of up-regulated or down-regulated genes in JASPAR database.](1414-431X-bjmbr-47-10-00834-gf004){#f04}

Discussion
==========

Down syndrome is a genetic condition in which a person has 47 chromosomes instead of the usual 46. In most cases, Down syndrome occurs when there is an extra copy of chromosome 21. In this study, we identified 581 DEGs in Down syndrome compared with normal tissue, and 8 DEGs were distributed in human chromosome 21. Finally, we identified 11 transcription factor motifs.

*HMGN1*, *RCAN1*, and *SON* were distributed in human chromosome 21. *HMGN1* and *RCAN1* have been reported to be associated with Down syndrome ([@B21],[@B22]), but the relationship between *SON* and Down syndrome has not been identified. *HMGN1* could regulate expression of methyl CpG-binding protein 2 (*MeCP2*), and may lead to neurodevelopmental disorders ([@B23]). Up-regulated expression of *RCAN1* was reported to cause Down syndrome-like immune dysfunction ([@B24]). The differential expression of *SON* was significant during developmental stages in human and mouse (except postnatal day 15; others were more than 1.5 times). *SON* is an SR-type protein involved in mRNA processing and gene expression, which is a splicing cofactor that contributes to an efficient splicing within cell cycle progression ([@B25]). Some SR proteins have been reported to influence the selection of alternative 5′ splice sites ([@B26]). All results suggested that *SON* may most likely be a candidate gene.

Another five genes (*CBR1*, *DYRK1A*, *ITSN1*, *TMEM50*, and *TTC3*) were also distributed in human chromosome 21. A previous study reported that the mRNA level of *CBR1* in Down syndrome samples was 1.8-fold greater than that in normal samples. In age-related neurodegenerative diseases, *DYRK1A* can regulate the expression of *RCAN1* ([@B27]). Trisomic mice injected in the hippocampus with short hairpin RNA against *DYRK1A* showed attenuation of synaptic plasticity defects ([@B28]). Recently, De la Torre et al. ([@B29]) reported that the *DYRK1A* inhibitor EGCG (the green tea flavonol, epigallocatechin gallate) could inhibit the activity of *DYRK1A* in the hippocampus area to prevent cognitive deficits in Down syndrome mouse models. *ITSN* and *TMEM50* have been reported to be related to Down syndrome ([@B30],[@B31]). Although there is no literature about *TTC3* and Down syndrome, *TTC3* is related to another seven genes distributed in human chromosome 21 ([@B32]). Therefore, *TTC3* is also a very likely candidate gene for Down syndrome.

In GO function annotation, some genes involved with regulation of neurological system processes were enriched in Down syndrome samples. Also, during KEGG pathway annotation, there were some genes related to Alzheimer\'s disease (a nervous system disease) ([@B33]). *PRKCZ* (potein kinase C, zeta), *EDNRB* (endothelin receptor type B), *CDK5* (cell division protein kinase 5), and *CACNA1A* (cav2.1 P/Q voltage-dependent calcium channel) were related to nervous system diseases. *PRKCZ* is thought to be responsible for maintaining long-term memory in the brain ([@B34]). *EDNRB* is a G protein-coupled receptor, which activates a phosphatidylinositol-calcium second messenger system ([@B35]). *CDK5* is involved in the processes of neuronal maturation and migration, phosphorylating the key intracellular adaptors of the reelin signaling chain ([@B36]). *CACNA1A* is also involved in neurotransmitter release ([@B37]). These genes are involved in the nervous system and they are likely related to Down syndrome, and further studies are needed to confirm this.

In addition, 11 significantly enriched transcription factor motifs (*PAX5*, *EGR1*, *XBP1*, *SREBP1*, *OLF1*, *MZF1*, *NFY*, *NFKAPPAB*, *MYCMAX*, *NFE2*, *RP58*) were identified. *XBP1*, *SREBP1*, *OLF1*, *NFY*, *NFKAPPAB*, *MYCMAX*, *NFE2*, and *RP58* were reportedly not associated with nervous system disease, whereas, in children with Down syndrome and acute lymphoblastic leukemia, *PAX 5* was found to be missing ([@B38]). Combined with our results, we considered that *PAX 5* may be involved in Down syndrome. In the hippocampus region of simian immunodeficiency virus encephalitis-induced neural dysfunction, *EGR1* is down-regulated ([@B39]). *MZF1* is predominantly expressed in neuronal tissue, and mutations in this gene are associated with neurological disorders, providing a potential link between this kinase and neurodegeneration ([@B40]).

In conclusion, *CBR1*, *DYRK1A*, *HMGN1*, *ITSN1*, *RCAN1*, *SON*, *TMEM50B*, and *TTC3* may be related to Down syndrome, and *SON* and *TTC3* were newly reported in our study. Also, the transcription factor motifs *PAX5*, *EGR1*, *XBP1*, *SREBP1*, *OLF1*, *MZF1*, *NFY*, *NFKAPPAB*, *MYCMAX*, *NFE2*, and *RP58* may contribute to the pathology of Down syndrome. However, further study is needed to confirm our results.
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